Monotherapy: Trajenta® is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance.1
Add-on combination: Trajenta® is indicated for use in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with: metformin, sulfonylurea (with or without metformin), metformin and empagliflozin, basal insulin (with or without metformin), when the therapy alone listed above, along with diet and exercise, does not provide adequate glycemic control.1
Click here for additional safety information and for a link to the Product Monograph discussing:1
- Contraindications in patients with diabetic ketoacidosis or type 1 diabetes mellitus
- Relevant warnings and precautions regarding heart failure, hypoglycemia, glycemic control, use with strong inducers of P-gp or CYP3A4 (monitoring recommended), use in patients with severe hepatic impairment, pancreatitis, hypersensitivity reactions, use in immunocompromised patients, blood glucose levels, hepatic function (should be assessed before starting treatment and periodically thereafter), use in patients with end-stage renal disease (ESRD) or on dialysis, fertility, skin lesions (monitoring recommended), bullous pemphigoid, use in pregnant and nursing women
- Conditions of clinical use, adverse reactions, drug interactions and dosing recommendations
The Product Monograph is also available by calling 1-800-263-5103 ext. 84633